| |
SRRE (95% CI)
|
No. Studies
|
SRRE (95% CI)
|
No. Studies
|
SRRE (95% CI)
|
No. Studies
|
SRRE (95% CI)
|
No. Studies
|
|---|
|
Overall Exposure
|
Neighborhood
|
Domestic
|
Household
|
|---|
|
Gender
|
|
Male
|
4.80 (1.96, 11.76)
|
7
|
5.71 (1.18, 27.54)
|
4
|
3.24 (1.63, 6.45)
|
5
|
2.40 (0.2, 26.70)
|
1
|
|
Female
|
7.83 (3.30, 18.57)
|
10
|
7.69 (1.91, 31.00)
|
5
|
6.13 (2.42, 15.51)
|
8
|
4.30 (1.20, 15.1)
|
1
|
|
Fiber type
|
|
Chrysotile
|
3.56 (0.65,20.82)
|
3
|
2.70 (0.03, 273.75)
|
2
|
4.30 (1.24, 14.94)
|
2
|
–
|
0
|
|
Mixed
|
7.63 (3.68, 15.82)
|
8
|
10.36 (3.24, 33.16)
|
7
|
7.40 (2.69, 20.37)
|
5
|
1.30 (0.80,2.30)
|
1
|
|
Not reported
|
2.66 (1.89, 3.74)
|
11
|
3.53 (1.27, 9.81)
|
6
|
2.70 (1.90, 3.85)
|
7
|
2.23 (1.06, 4.70)
|
4
|
|
Region
|
|
Europe
|
5.44 (3.16, 9.37)
|
13
|
7.59 (3.24, 17.77)
|
10
|
4.82 (2.46, 9.44)
|
9
|
2.37 (1.34,4.19)
|
4
|
|
USA/Canada
|
2.15 (1.01, 4.56)
|
6
|
0.77 (0.30, 1.95)
|
2
|
3.36 (1.68, 6.72)
|
5
|
–
|
0
|
|
South Africa/Egypt
|
22.27 (6.35, 81.32)
|
2
|
22.27 (6.35, 81.32)
|
2
|
–
|
0
|
–
|
0
|
|
Australia/South Pacific
|
2.64 (0.92, 7.57)
|
3
|
2.55 (1.09, 4.64)
|
2
|
2.08 (0.80, 5.42)
|
1
|
5.53 (0.15,205.3)
|
2
|
|
Study Type
|
|
Cohort
|
12.62 (6.30, 25.26)
|
5
|
11.59 (4.37, 30.79)
|
4
|
8.17 (2.77, 24.13)
|
3
|
–
|
0
|
|
Case-Control
|
2.12 (1.76, 2.56)
|
19
|
3.37 (2.08, 5.46)
|
12
|
2.88 (2.05, 4.03)
|
12
|
2.41 (1.30, 4.48)
|
6
|
- †: p-value< 0.05 for statistically significant SRRE if 95%CI does not include 1
